Literature DB >> 6831769

The idiotypic specificities of lymphocytes in human monoclonal gammopathies: analysis with the fluorescence activated cell sorter.

A L Carmagnola, M Boccadoro, M Massaia, A Pileri.   

Abstract

Four monoclonal IgG kappa gammopathies were studied with anti-idiotypic sera and the percentage of lymphocytes bearing such idiotypes was evaluated with a fluorescence activated cell sorter (FACS). A large percentage (10-15%) of peripheral lymphocytes bearing receptors with the same idiotypic specificities as the M component was observed in multiple myeloma (MM) and in monoclonal gammopathy of undetermined significance (MGUS), suggesting a malignant origin for both these diseases. Capping-endocytosis and resynthesis experiments showed that these idiotypic receptors were not simply adsorbed on the cell membrane, but actually synthesized by the cells bearing them. Experiments performed after effective conventional chemotherapy showed a strong reduction of the idiotypic compartment in only one MM patient.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6831769      PMCID: PMC1536741     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  15 in total

1.  Idiotypic studies on myeloma B cells.

Authors:  A Van Acker; F Conte; N Hulin; J Urbain
Journal:  Eur J Cancer       Date:  1979-05       Impact factor: 9.162

2.  Idiotypic specificity of surface immunoglobulin and the maturation of leukemic bone-marrow-derived lymphocytes.

Authors:  S M Fu; R J Winchester; T Feizi; P D Walzer; H G Kunkel
Journal:  Proc Natl Acad Sci U S A       Date:  1974-11       Impact factor: 11.205

3.  Multiple myeloma and benign monoclonal gammopathy: differentiation by immunofluorescence of lymphocytes.

Authors:  F D Lindström; W R Hardy; B J Eberle; R C Williams
Journal:  Ann Intern Med       Date:  1973-06       Impact factor: 25.391

4.  Monoclonal B-lymphocytes in peripheral blood of patients with plasma cell myeloma. Relation to activity of the disease.

Authors:  H Mellstedt; D Pettersson; G Holm
Journal:  Scand J Haematol       Date:  1976-02

5.  Idiotype-bearing and antigen-binding receptors produced by blood T lymphocytes in a case of human myeloma.

Authors:  J L Preud'homme; M Klein; S Labaume; M Seligmann
Journal:  Eur J Immunol       Date:  1977-12       Impact factor: 5.532

6.  Monoclonal lymphocyte population in human plasma cell myeloma.

Authors:  H Mellstedt; S Hammarström; G Holm
Journal:  Clin Exp Immunol       Date:  1974-07       Impact factor: 4.330

7.  Shared idiotypes of human peripheral blood B and T lymphocytes.

Authors:  T Lea; O T Førre; T E Michaelsen; J B Natvig
Journal:  J Immunol       Date:  1979-06       Impact factor: 5.422

8.  Monoclonal gammopathy of undetermined significance. Natural history in 241 cases.

Authors:  R A Kyle
Journal:  Am J Med       Date:  1978-05       Impact factor: 4.965

9.  A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival.

Authors:  B G Durie; S E Salmon
Journal:  Cancer       Date:  1975-09       Impact factor: 6.860

10.  Studies on the clonal origin of multiple myeloma. Use of individually specific (idiotype) antibodies to trace the oncogenic event to its earliest point of expression in B-cell differentiation.

Authors:  H Kubagawa; L B Vogler; J D Capra; M E Conrad; A R Lawton; M D Cooper
Journal:  J Exp Med       Date:  1979-10-01       Impact factor: 14.307

View more
  3 in total

1.  Mixed lymphocyte reaction in human monoclonal gammopathies.

Authors:  A L Carmagnola; M Boccadoro; A Pileri
Journal:  Experientia       Date:  1983-10-15

2.  Severe deficiency of B lymphocytes in peripheral blood from multiple myeloma patients.

Authors:  L M Pilarski; M J Mant; B A Ruether; A Belch
Journal:  J Clin Invest       Date:  1984-10       Impact factor: 14.808

3.  Immunoglobulin secretion by peripheral blood and bone marrow B cells in patients with multiple myeloma. Studies by the reverse haemolytic plaque assay.

Authors:  F Dammacco; A Vacca; E Altomare; N Campobasso
Journal:  Clin Exp Immunol       Date:  1984-09       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.